Signet Laboratories, Inc. Announces Availability Of Polyclonal Hepsin

DEDHAM, Mass., Nov. 17 /PRNewswire/ -- Signet Laboratories, Inc., a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, today announced the availability of polyclonal Hepsin antibody.

Hepsin is a cell surface serine protease upregulated in prostate cancer. The functional significance of this upregulation is unknown. Recent studies have reported that Hepsin may play a role in the disorganization of the basement membrane and metastasis.

Improved screening and early diagnosis have reduced mortality, but the need exists for treatment options and prognostic markers for advanced metastatic and hormone resistant disease. “Hepsin is a promising marker for prostate cancer since it may help researchers better understand prostate cancer progression and metastasis,” said Angela Thomas, Immunohistochemistry Product Manager for Signet Laboratories.

One million men in the United States suffer from prostate cancer. In 2005 233,000 new cases of prostate cancer will be diagnosed, and over 30,000 men will die from the disease.

About Signet Laboratories, Inc.

Signet Laboratories, Inc. (Signet, Dedham, MA) is a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease. Signet was created in 1989 as a commercial spinout of Johnson & Johnson’s Cambridge Research Laboratories, Inc. (CRL, Cambridge, MA).

The Company was founded to continue the mission originally established at CRL -- the early detection and recurrence monitoring of patients with cancer and infectious disease. Signet has developed patented technology for diagnosis and recurrence monitoring and for risk assessment of asymptomatic patients in these areas. For more than a decade, the Company has aggressively maintained licensing and development programs, which are responsible for its broad patent and intellectual estate. Contact Information Company Contact Immunohistochemistry Contact Colleen Scott Angela Thomas Signet Laboratories, Inc. Signet Laboratories, Inc. 180 Rustcraft Road 180 Rustcraft Road Dedham, MA 02026 Dedham, MA 02026 Phone: 781.915.1404 Phone: 781.915.1417 Fax: 781.461.2456 Fax: 781.461.2456 cscott@signetlabs.comathomas@signetlabs.com

Signet Laboratories, Inc.

CONTACT: Company Contact: Colleen Scott of Signet Laboratories, Inc., +1-781-915-1404, cscott@signetlabs.com; or Immunohistochemistry Contact:Angela Thomas of Signet Laboratories, Inc., +1-781-915-1417,athomas@signetlabs.com

MORE ON THIS TOPIC